Mice heterozygous for a Brca1 or Brca2 mutation display distinct mammary gland and ovarian phenotypes in response to diethylstilbestrol

Cancer Research

Volumn 60, Issue 13, 2000, Pages 3461-3469

  Bennett, L Michelle ^a   McAllister, Kimberly A ^a   Malphurs, Jason ^a   Ward, Toni ^a   Collins, N Keith ^a   Seely, John C ^b   Gowen, Lori C ^c,d   Koller, Beverly H ^c   Davis, Barbara J ^a   Wiseman, Roger W ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b PATHCO Inc   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIETHYLSTILBESTROL;

ADENOMYOSIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER SUSCEPTIBILITY; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DNA REPAIR; EPITHELIUM HYPERPLASIA; FEMALE; FIBROSIS; GENE MUTATION; HYPERKERATOSIS; MAMMARY GLAND FUNCTION; METRITIS; MOUSE; NONHUMAN; ONCOGENE; OVARY FUNCTION; PRIORITY JOURNAL; VAGINA EPITHELIUM;

ANIMALS; BRCA2 PROTEIN; CARCINOGENS; CHIMERA; CROSSES, GENETIC; DIETHYLSTILBESTROL; ENDOMETRIOSIS; EPITHELIAL CELLS; FALLOPIAN TUBES; FEMALE; FIBROSIS; GENES, BRCA1; GENETIC MARKERS; HETEROZYGOTE; HYPERTROPHY; INFLAMMATION; MAMMARY GLANDS, ANIMAL; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, TRANSGENIC; MUSCLE, SMOOTH; NEOPLASM PROTEINS; OVARY; PHENOTYPE; TRANSCRIPTION FACTORS; UTERUS; VAGINA;

EID: 18244428268     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Rahman, N., and Stratton, M. The genetics of breast cancer susceptibility. Annu. Rev. Genet., 32: 95-120, 1998.
2. Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., Bishop, D. T., Weber, B., Lenoir, G., Chang-Claude, J., Sobol, H., Teare, M. D., Struewing, J., Arason, A., Scherneck, S., Peto, J., Rebbeck, T. R., Tonin, P., Neuhausen, S., Barkardottir, R., Eyfjord, J., Lynch, H., Ponder, B. A. J., Gayther, S. A., Birch, J. M., Lindblom, A., Stoppa-Lyonnet, D., Bignon, Y., Borg, A., Hamann, U., Haites, N., Scott, R. J., Maugard, C. M., and Vasen, H. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am. J. Hum. Genet., 62: 676-689, 1998.
3. Scully, R., Chen, J., Plug, A., Xiao, Y., Weaver, D., Feunteun, J., Ashley, T., and Livingston, D. M. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell, 88: 265-275, 1997.
4. Patel, K. J., Yu, V. P. C., Lee, H. S., Corcoran, A., Thistlethwaite, F. C., Evans, M. J., Colledge, W. H., Friedman, L. S., Ponder, B. A. J., and Venkitaraman, A. R. Involvement of Brca2 in DNA repair. Mol. Cell, 1: 347-357, 1998.
5. Gowen, L. C., Avrutskaya, A. V., Latour, A. M., Koller, B. H., and Leadon, S. A. BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science (Washington DC), 281: 1009-1012, 1998.
6. Chen, J. J., Silver, D., Cantor, S., Livingston, D. M., and Scully, R. BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. Cancer Res., 59: 1752s-1756s, 1999.
7. Morimatsu, M., Donoho, G., and Hasty, P. Cells deleted for Brca2 COOH terminus exhibit hypersensitivity to γ-radiation and premature senescence. Cancer Res., 58: 3441-3447, 1998.
8. Zhong, Q., Chen, C. F., Li, S., Chen, Y., Wang, C. C., Xiao, J., Chen, P. L., Sharp, Z. D., and Lee, W. H. Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science (Washington DC), 285: 747-750, 1999.
9. Somasundaram, K., Zhang, H. B., Zeng, Y. X., Houvras, Y., Peng, Y., Zhang, H. X., Wu, G. S., Licht, J. D., Weber, B. L., and El Deiry, W. S. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21(WAF1/CiP1). Nature (Lond.), 389: 187-190, 1997.
10. Wu, L. C., Wang, Z. W., Tsan, J. T., Spillman, M. A., Phung, A., Xu, X. L., Yang, M-C. W., Hwang, L-Y., Bowcock, A. M., and Baer, R. Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat. Genet., 14: 430-440, 1996.
11. Hsu, L-C., and White, R. BRCA1 is associated with the centrosome during mitosis. Proc. Natl. Acad. Sci. USA, 95: 12983-12988, 1998.
12. Hu, Y-F., Hao, Z-L., and Li, R. Chromatin remodeling and activation of chromosomal DNA replication by an acidic transcriptional activation domain from BRCA1. Genes Dev., 13: 637-642, 1999.
13. Fan, S., Wang, J. A., Yuan, R., Ma, Y., Meng, Q., Erdos, M. R., Pestell, R. G., Yuan, F., Auborn, K. J., Goldberg, I. D, and Rosen, E. M. BRCAI inhibition of estrogen receptor signaling in transfected cells. Science (Washington DC), 284: 1354-1356, 1999.
14. Sharan, S. K., Morimatsu, M., Albrecht, U., Lim, D. S., Regel, E., Dinh, C., Sands, A., Eichele, G., Hasty, P., and Bradley, A. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature (Lond.), 386: 804-810, 1997.
15. Chen, P-L., Chen, C-F., Chen, Y., Xiao, J., Sharp, Z. D., and Lee, W-H. The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methane-sulfonate treatment. Proc. Natl. Acad. Sci. USA, 95: 5287-5292, 1998.
16. Marmorstein, L. Y., Ouchi, T., and Aaronson, S. A. The BRCA2 gene product functionally interacts with p53 and RAD51. Proc. Natl. Acad. Sci. USA. 95: 13869-13874, 1998.
17. Baer, R., and Lee, W. H. Functional domains of the BRCA1 and BRCA2 proteins. J. Mamm. Gland Biol. Neoplasia, 1: 403-412, 1998.
18. Catteau, A., Harris, W. H., Xu, C. F., and Solomon, E. Methylation of the BRCAI promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene, 18: 1957-1965, 1999.
19. Blackshear, P. E., Goldsworthy, S. M., Foley, J. F., McAllister, K. A., Bennett, L. M., Collins, N. K., Bunch, D. O., Brown, P., Wiseman, R. W., and Davis, B. J. Brca1 and Brca2 expression patterns in mitotic and meiotic cells of mice. Oncogene, 16: 61-68, 1998.
20. Gudas, J. M., Nguyen, H., Li, T., and Cowan, K. H. Hormone-dependent regulation of BRCA1 in human breast cancer cells. Cancer Res., 55: 4561-4565, 1995.
21. Marks, J. R., Huper, G., Vaughn, J. P., Davis, P. L., Norris, J., McDonnell, D. P., Wiseman, R. W., Futreal, P. A., and Inglehart, J. D. BRCA1 expression is not directly responsive to estrogen. Oncogene, 14: 115-121, 1997.
22. Phillips, K. W., Goldsworthy, S. M., Bennett, L. M., Brownlee, H. A., Wiseman, R. W., and Davis, B. J. Brca1 is expressed independently of hormonal stimulation in the mouse ovary. Lab. Invest., 76: 419-425, 1997.
23. Xu, C., Chambers, J., and Solomon, E. Complex regulation of the BRCA1 gene. J. Biol. Chem., 272, 20994-20997, 1997.
24. Brunet, J. S., Ghadirian, P., Rebbeck, T. R., Lerman, C., Garber, J. E., Tonin, P. N., Abrahamson, J., Foulkes, W. D., Daly, M., Wagner-Costalas, J., Godwin, A., Olopade, O. I., Moslehi, R., Liede, A., Futreal, P. A., Weber, B. L., Lenoir, G. M., Lynch, H. T., and Narod, S. A. Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J. Natl. Cancer Inst., 90: 761-766, 1998.
25. Ursin, G., Henderson, B. E., Haile, R. W., Pike, M. C., Zhou, N., Diep, A., and Bernstein, L. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Res., 57: 3678-3681, 1997.
26. Narod, S. A., Risch, H., Moslehi, R., Dorum, A., Neuhausen, S., Olsson, H., Provencher, D., Radice, P., Evans, G., Bishop, S., Brunet, J. S., and Ponder, B. A. J. Oral contraceptives and the risk of hereditary ovarian cancer. N. Engl. J. Med., 339: 424-428, 1998.
27. Rebbeck, T. R., Levin, A. M., Eisen, A., Snyder, C., Watson, P., Cannon-Albright, L., Issacs, C., Olopade, O., Garber, J. E., Godwin, A. K., Daly, M. B., Narod, S. A., Neuhausen, S. L., Lynch, H. T., and Weber, B. L. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J. Natl. Cancer Inst., 91: 1475-1479, 1999.
28. Marselos, M., and Tomatis, L. Diethylstilboestrol. I. Pharmacology, toxicology and carcinogenicity in humans. Eur. J. Cancer, 28A: 1182-1189, 1992.
29. Herbst, A. L., Ulfelder, H., and Poskanzer, D. C. Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumor appearance in young women. N. Engl. J. Med., 284: 878-881, 1971.
30. IARC. IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man, Supplement 7, Overall Evaluations of Carcinogenicity: An Updating of the IARC Monographs Vol. 1-42, pp. 273-278. Lyon, France: IARC, 1987.
31. Beral, V., and Colwell, L. Randomised trial of high doses of stilboestrol and ethisterone in pregnancy: long-term follow-up of mothers. Br. Med. J., 281: 1098-1101, 1980.
32. Colton, T., Greenberg, E. R., Noller, K., Resseguid, L., Van Bennekom, C., Heeren, T., and Zhang, Y. Breast cancer in mothers prescribed diethylstilbestrol in pregnancy. J. Am. Med. Assoc., 269: 2096-2100, 1993.
33. Bibbo, M., Haenszel, W. M., Wied, G. L., Hubby, M., and Herbst, A. L. A twenty-five-year follow-up study of women exposed to diethylstilbestrol during pregnancy. N. Engl. J. Med., 298: 763-767, 1978.
34. Greenberg, E. R., Barnes, A. B., Resseguie, L., Barrett, J. A., Burnside, S., Lanza, L. L., Neff, R. K., Stevens, M., Young, M. D., and Colton, T. Breast cancer in mothers given diethylstilbestrol in pregnancy. N. Engl. J. Med., 311: 1393-1398, 1984.
35. Hadjimichael, O. C., Meigs, J. W., Falcier, F. W., Thompson, W. D., and Flannery, J. T. Cancer risk among women exposed to exogenous estrogens during pregnancy. J. Natl. Cancer Inst., 73: 831-834, 1984.
36. Hatch, E. E., Palmer, J. R., Titus-Ernstoff, L., Noller, K. L., Kaufman, R. H., Mittendorf, R., Robboy, S. J., Hyer, M., Cown, C. M., Adam, E., Colton, T., Hartge, P., and Hoover, R. N. Cancer risk in women exposed to diethylstilbestrol in utero. J. Am. Med. Assoc., 280: 630-634, 1998.
37. Huckell, C., Laskin, J., and Gelmon, K. Premenopausal breast cancer after in utero exposure to stilboestrol. Lancet, 348: 331, 1996.
38. Duax, W. L., Swenson, D. C., Strong, P. D., Korach, K. S., McLachlan, J., and Metzler, M. Molecular structures of metabolites and analogues of diethylstilbestrol and their relationship to receptor binding and biological activity. Mol. Pharmacol., 26: 520-525, 1984.
39. Lupulescu, A. Estrogen use and cancer risk: a review. Exp. Clin. Endocrinol., 101: 204-214, 1993.
40. Yager, J. D., and Liehr, J. G. Molecular mechanisms of estrogen carcinogenesis. Annu. Rev. Pharmacol. Toxicol., 36: 203-232, 1996.
41. Gray-Nelson, K., Sakai, Y., Steed, T., and McLachlan, J. Exposure to diethylstilbestrol during a critical developmental period of the mouse reproductive tract leads to persistent induction of two estrogen-regulated genes. Cell Growth Differ., 5: 595-606, 1994.
42. Miller, C., Degenhardt, K., and Sassoon, D. A. Fetal exposure to DES results in de-regulation of Wnt7a during uterine morphogenesis. Nat. Genet., 20: 228-230, 1998.
43. Tomooka, Y., and Bern, H. A. Growth of mouse mammary glands after neonatal sex hormone treatment. J. Natl. Cancer Inst., 69: 1347-1352, 1982.
44. Gass, G. H., Coats, D., and Graham, N. Carcinogenic dose-response curve to oral diethylstilbestrol. J. Natl. Cancer Inst., 33: 971-977, 1964.
45. Greenman, D. L., Highman, B., Chen, J. J., Schieferstein, G. J., and Norvell, M. J. Influence of age on induction of mammary tumors by diethylstilbestrol in C3H/HeN mice with low murine mammary tumor virus titer. J. Natl. Cancer Inst., 77: 891-898, 1986.
46. Robinson, D. The International Life Science Institute's role in the evaluation of alternative methodologies for the assessment of carcinogenic risk. Toxicol. Pathol., 26: 474-475, 1998.
47. Tennant, R. W., Stasiewicz, S., Mennear, J., French, J. E., and Spalding, J. W. Genetically altered mouse models for identifying carcinogens. In: D. B. McGregor, J. M. Rice, and S. Venitt (eds.), The Use of Short-and Medium-Term Tests for Carcinogens and Data on Genetic Effects in Carcinogenic Hazard Evaluation, Vol. 146, pp. 123-150. Lyon, France: IARC, 1999.
48. Eastin, W. C., Haseman, J. K., Mahler, J. F., and Bucher, J. R. The National Toxicology Program evaluation of genetically altered mice as predictive models for identifying carcinogens. Toxicol. Pathol., 26: 461-473, 1998.
49. Gowen, L. C., Johnson, B. L., Lalour, A. M., Sulik, K. K., and Koller, B. H. Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat. Genet., 12: 191-194, 1996.
50. Bennett, L. M., McAllister, K. A., Blackshear, P. E., Malphurs, J., Goulding, G., Collins, N. K., Ward, T., Bunch, D. O., Eddy, E. M., Davis, B. J., and Wiseman, R. W. Brca2-null embryonic surivial is prolonged on the BALB/c genetic background. Mol. Carcinog., in press, 2000.
51. Russo, I. H., Tewari, M., and Russo, J. Morphology and Development of the Rat Mammary Gland, p. 239. Berlin: Springer, 1989.
52. Siegel, S. Nonparametric Statistics for the Behavioral Sciences. New York: McGraw-Hill Book Company, 1956.
53. Xu, X. L., Wagner, K. U., Larson, D., Weaver, Z., Li, C. L., Ried, T., Henningausen, L., Wynshaw-Boris, A., and Deng, C. X. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat. Genet., 22: 37-43, 1999.
54. Cressman, V. L., Backlund, D. C., Avrutskaya, A. V., Leadon, S. A., Godfrey, V., and Koller, B. H. Growth retardation. DNA repair defects, and lack of spermatogenesis in BRCA1-deficient mice. Mol. Cell. Biol., 19: 7061-7075, 1999.
55. Lane, T. F., Deng, C., Elson, A., Lyu, M. S., Kozak, C. A., and Leder, P. Expression of Brca1 is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice. Genes Dev., 9: 2712-2722, 1995.
56. Marquis, S. T., Rajan, J. V., Wynshaw-Boris, A., Xu, J., Yin, G-Y., Abel, K. J., Weber, B. L., and Chodosh, L. A. The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nat. Genet., 11: 17-26, 1995.
57. Lee, H., Trainer, A. H., Friedman, L. S., Thisllethwaite, F. C., Evans, M. J., Ponder, B. A. J., and Venkitaraman, A. R. Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, Brca2. Mol. Cell, 4: 1-10, 1999.
58. 2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol. Cell, 3: 389-395, 1999.
59. Chodosh, L. A., D'Cruz, C. M., Gardener, H. P., Ha, S. I., Marquis, S. T., Rajan, J. V., Stairs, D. B., Wang, J. Y., and Wang, M. Mammary gland development, reproductive history and breast cancer risk. Cancer Res., 59, 1765s-1772s, 1999.
60. Russo, J., and Russo, I. H. Toward a unified concept of mammary carcinogenesis. In: C. E. A. Aldez (ed.), Etiology of Breast and Gynecological Cancers, pp. 1-16. New York: Wiley-Liss, 1997.
61. Cardiff, R. D. Are the TDLU of the human the same as the LA of mice? J. Mamm. Gland Biol. Neoplasia, 3: 3-5, 1998.
62. Jones, L. A., and Bern, H. A. Cervicovaginal and mammary gland abnormalities in BALB/cCrg1 mice treated neonatally with progesterone and estrogen, alone or in combination. Cancer Res., 39: 2560-2567, 1979.
63. Welch, C. W., and Nagasawa, H. Prolactin and murine mammary tumorigenesis: a review. Cancer Res., 37: 951-963, 1977.
64. Greenman, D. L., Highman, B., Kodell, R. L., Morgan, K. T., and Norvell, M. Neoplastic and nonneoplastic responses to chronic feeding of diethylstilbestrol in C3H mice. J. Toxicol. Environ. Health, 14: 551-567, 1984.
65. Kinzler, K. W., and Vogelslein, B. Gatekeepers and caretakers. Nature (Lond.), 386: 761-763, 1997.
66. Schuyer, M., and Berns, E. M. J. J. Is Tp53 dysfunction required for BRCA1-associated carcinogenesis?. Mol. Cell. Endocrinol., 155: 143-152, 1999.
67. Cressman, V. L., Backlund, D. C., Hicks, E. M., Gowen, L. C., Godfrey, V., and Koller, B. H. Mammary tumor formation in p53-and Brca1-deficient mice. Cell Growth Differ., 10: 1-10, 1999.
68. Crook, T., Brooks, L. A., Crossland, S., Osin, P., Barker, K. T., Waller, J., Philip, E., Smith, P. D., Yulug, I., Peto, J., Parker, G., Allday, M. J., Crompton, M. R., and Gusterson, B. A. p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1-and BRCA2-associated breast tumors. Oncogene, 17: 1681-1689, 1998.
69. Newbold, R. R. Cellular and molecular effects of developmental exposure to diethylstilboestrol: implications for other environmental estrogens. Environ. Health Perspect., 103: 95-97, 1995.
70. Marselos, M., and Tomatis, L. Diethylstilboestrol. II. Pharmacology, toxicology and carcinogenicity in experimental animals. Eur. J. Cancer, 29A: 149-155, 1993.